PNU 177864 hydrochloride structure
|
Common Name | PNU 177864 hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1783978-03-9 | Molecular Weight | 438.89 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H22ClF3N2O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PNU 177864 hydrochloridePNU-177864 hydrochloride is a potent, selective and orally active dopamine D3 receptor antagonist. PNU-177864 hydrochloride is structurally consistent with a cationic amphiphilic drug (CAD) and induces phospholipidosis in vivo. PNU-177864 hydrochloride antischizophrenic activity[1][2]. |
| Name | PNU-177864 hydrochloride |
|---|
| Description | PNU-177864 hydrochloride is a potent, selective and orally active dopamine D3 receptor antagonist. PNU-177864 hydrochloride is structurally consistent with a cationic amphiphilic drug (CAD) and induces phospholipidosis in vivo. PNU-177864 hydrochloride antischizophrenic activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
D3 Receptor |
| In Vivo | PNU-177864 (12.5-200 mg/kg; oral gavage; daily; for 2-4 weeks; Sprague-Dawley rats) treatment induces phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles[1]. Animal Model: Male and female Sprague-Dawley rats (8-9-week-old)[1] Dosage: 12.5 mg/kg, 50 mg/kg (for 2 weeks), or 200 mg/kg; 8 mg/kg, 25 mg/kg, or 80 mg/kg (for 4 weeks) Administration: Oral gavage; daily; for 2-4 weeks Result: Induced phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles. |
| References |
| Molecular Formula | C18H22ClF3N2O3S |
|---|---|
| Molecular Weight | 438.89 |